

ASSOCIATE EDITOR: MARKKU KOULU

Prodrugs—from Serendipity to Rational Design

Kristiina M. Huttunen, Hannu Raunio, and Jarkko Rautio

School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland

Abstract	A
I. Introduction	A
II. History and the present of prodrug design	B
III. Rationale for prodrug design	D
A. Improving formulation and administration	E
B. Enhancing permeability and absorption	F
C. Changing the distribution profile	I
D. Protecting from rapid metabolism and excretion	I
E. Overcoming toxicity problems	I
F. Managing the life cycle	L
IV. Preclinical and clinical considerations of prodrug bioconversion	M
A. Esterase-catalyzed hydrolysis of prodrugs	M
B. Prodrug bioactivation by cytochrome P450 enzymes	N
1. Anticancer drugs	O
2. Cardiovascular drugs	P
3. Opioid analgesics	S
V. Conclusions	S
Acknowledgments	T
References	T

Abstract—The prodrug concept has been used to improve undesirable properties of drugs since the late 19th century, although it was only at the end of the 1950s that the actual term *prodrug* was introduced for the first time. Prodrugs are inactive, bioreversible derivatives of active drug molecules that must undergo an enzymatic and/or chemical transformation in vivo to release the active parent drug, which can then elicit its desired pharmacological effect in the body. In most cases, prodrugs are simple chemical derivatives that are only one or two chemical or enzymatic steps away from the active parent drug. However, some prodrugs lack an obvious carrier or promoiety but instead result from a molecular modification of the prodrug it-

self, which generates a new active compound. Numerous prodrugs designed to overcome formulation, delivery, and toxicity barriers to drug utilization have reached the market. In fact, approximately 20% of all small molecular drugs approved during the period 2000 to 2008 were prodrugs. Although the development of a prodrug can be very challenging, the prodrug approach represents a feasible way to improve the erratic properties of investigational drugs or drugs already on the market. This review introduces in depth the rationale behind the use of the prodrug approach from past to present, and also considers the possible problems that can arise from inadequate activation of prodrugs.

I. Introduction

In simplified terms, prodrugs are masked forms of active drugs that are designed to be activated after an

enzymatic or chemical reaction once they have been administered into the body (Fig. 1) (Ettmayer et al., 2004; Stella et al., 2007; Rautio et al., 2008; Rautio, 2010; Stella, 2010). Prodrugs are considered to be inactive or at least significantly less active than the released drugs; therefore, salts of active agents and drugs, whose metabolites contribute to the overall pharmacological response, are not included in this definition. The rationale behind the use of prodrugs is generally to optimize the so-called “drug-like” properties [i.e., absorption, dis-

Address correspondence to: Kristiina M. Huttunen, School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland. E-mail: kristiina.huttunen@uef.fi

This article is available online at <http://pharmrev.aspetjournals.org>.
doi:10.1124/pr.110.003459.

B

HUTTUNEN ET AL.




FIG. 1. A simplified illustration of the prodrug concept.

tribution, metabolism, and excretion (ADME¹) properties] because they can cause considerable problems in subsequent drug development, if unfavourable (Table 1). In addition, the prodrug strategy has been used to increase the selectivity of drugs for their intended target. This can not only improve the efficacy of the drug but also decrease systemic and/or unwanted tissue/organ-specific toxicity (T). Development of a prodrug with improved properties may also represent a life-cycle management opportunity.

Unfortunately, the general opinion among scientists still is that prodrugs are “an act of desperation”; they are considered only when problems are encountered with the original drug candidate. The design of an appropriate prodrug should never be viewed as a last resort. If anything, this alternative should be considered in the early stages of preclinical development, bearing in mind that prodrugs may alter the tissue distribution, efficacy, and even toxicity of the parent drug. Therefore, modifying the ADME properties of the parent drug requires a comprehensive understanding of the physicochemical and biological behavior of the drug candidate. Although prodrug design is very challenging, it can still be more feasible and faster than searching for an entirely new

therapeutically active agent with suitable ADME/T properties. Another fallacy is that prodrugs are simply of academic interest and do not have industrial applications in attempts to overcome bioavailability and toxicity problems. A very good indication of the success of the prodrug approach can be obtained by examining the prevalence of prodrugs on the market. It might come as a surprise to many people that currently approximately 10% of all globally marketed medicines can be classified as prodrugs, and in 2008 alone, 33% of all approved small-molecular-weight drugs were prodrugs (Rautio, 2010; Stella, 2010). Despite these impressive numbers, we have only begun to appreciate the full potential of the prodrug approach in modern drug development, and many novel prodrug innovations await discovery.

II. History and the Present of Prodrug Design

Adrien Albert first introduced the term “pro-drug” in 1958 (Albert, 1958). A few decades later, he apologized for having invented such an inaccurate term, because “predrug” would have been a more descriptive term. However, by that time, the original version was used too widely to be changed. Nonetheless, the prodrug concept has been invented long before Albert’s publication. The first intentionally designed prodrug is most probably methenamine (or hexamine), which was introduced 1899 by Schering. Methenamine releases 6 Eq of the antibacterial formaldehyde along with 4 Eq of ammonium ions in acidic urine and serves as a good example of a site-selective prodrug (Testa, 2004; Stella et al., 2007). At the same time, Bayer introduced aspirin (acetylsalicylic acid) as a less irritating form of the anti-inflammatory agent sodium salicylate. However, it remains a matter of debate whether aspirin is a true prodrug or not. Although it was intended to work as a prodrug, aspirin

¹Abbreviations: ADME, absorption, distribution, metabolism, and excretion; ADME/T absorption, distribution, metabolism, excretion, and toxicity; araC, arabinofuranosyl cytidine (cytarabine); CES, carboxylesterase; DMAE, 1-(2',5'-dimethoxyphenyl)-2-aminoethanol; EM, extensive metabolizer; EXP3174, 2-*n*-butyl-4-chloro-1-((2'-(1*H*-tetrazol-5-yl)biphenyl-4-yl)methyl)imidazole-5-carboxylic acid; 5-FU, 5-fluorouracil; FDA, United States Food and Drug Administration; LDL, low-density lipoprotein; MB07133, 4-amino-1-(5-*O*-(2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl)arabinofuranosyl)-2(1*H*)-pyrimidinone; P450, cytochrome P450; PM, poor metabolizer; PMEA, 9-(2-phosphonomethoxyethyl)adenine; PPI, proton pump inhibitor; PR-104, 2-((2-bromoethyl)-2-(((2-hydroxyethyl)amino)carbonyl)-4,6-dinitroanilino)ethyl methanesulfonate phosphate ester; TPZ, tirapazamine (SR 4233).

TABLE 1
The rationale behind the use of the prodrug approach

Barrier to Overcome	Examples of Applicable Prodrugs	Preferable Site of Bioconversion	Common Functional Groups Amenable to the Prodrug Method
Formulation and administration <ul style="list-style-type: none">• Low aqueous solubility• Low shelf-life• Pain or irritation after local administration• Unpleasant taste/odor	Introducing ionizable or polar neutral group <ul style="list-style-type: none">• Phosphates• Amino acid esters/amides• Sugar derivatives	During or after absorption <ul style="list-style-type: none">• at the brush border of enterocytes• in the systemic circulation or after local administration• in the systemic circulation by hydrolytic enzymes	-OH -SH -NH (via spacer) -COOH
Absorption <ul style="list-style-type: none">• Poor membrane permeation• Low stability in GI tract• Substrate of efflux transporters	Masking polar ionized/non-ionized group(s) <ul style="list-style-type: none">• Alkyl/aryl esters• Amino acid esters/amides	After absorption <ul style="list-style-type: none">• in the systemic circulation by hydrolytic enzymes	-OH -SH -NH -COOH -OPO(OH) ₂
Distribution <ul style="list-style-type: none">• Lack of site specificity• High degree of plasma protein binding	Targeting cell- or tissue-specific transporters or enzymes <ul style="list-style-type: none">• Amino acid esters/amides• Sugar derivatives	In the target tissue <ul style="list-style-type: none">• by cell-specific hydrolytic enzymes or• oxidoreductases	-OH -SH -NH -COOH
Metabolism and excretion <ul style="list-style-type: none">• Short duration of action	Masking metabolically labile group(s) or polar ionized/nonionized group(s) <ul style="list-style-type: none">• Alkyl/aryl esters• Amino acid esters/amides	After absorption <ul style="list-style-type: none">• in the systemic circulation• in the target tissue by hydrolytic enzymes	-OH -SH -NH -COOH -OPO(OH) ₂
Toxicity <ul style="list-style-type: none">• Lack of site specificity	Targeting tissue-specific enzymes or divergent conditions of target tissue <ul style="list-style-type: none">• Various different prodrug methods	In the target tissue <ul style="list-style-type: none">• by cell-specific enzymes• because of altered pH or hypoxia	Depending on the selected prodrug method (these prodrugs are often bioprecursors)
Life-cycle management	Introducing any kind of promoiety <ul style="list-style-type: none">• Various different prodrug methods	Depending on the selected prodrug method	Depending on the selected prodrug method (these prodrugs are often carrier-linked prodrugs)

GI, gastrointestinal.

inhibits irreversibly cyclooxygenase, the enzyme responsible for formation of the key biological mediators, prostaglandins and thromboxanes, by acetylating one hydroxyl group of serine residue (Ser 530) in the active site of the enzyme, while the parent drug, salicylic acid, is a weak reversible inhibitor of cyclooxygenase. In this respect, aspirin cannot be considered as a prodrug (Vane and Botting, 2003). However, aspirin is rapidly hydrolyzed in the intestinal wall and liver, as well as in the blood to salicylic acid, which means that it acts, in fact, like a prodrug (Testa and Mayer, 2003).

Many decades elapsed until Bayer introduced their next prodrug, the antibiotic prontosisil, in 1935. However, prontosisil was not intentionally developed as a prodrug, because only later in the same year was it found to release an active agent, *para*-aminophenylsulfonamide, by reductive enzymes. The launch of prontosisil gave rise to the second generation of sulfonamide prodrugs, because the sulfanilamide moiety was easy to link to other molecules (Bentley, 2009). In a similar way, Roche discovered the prodrug activity of the antituberculosis drug isoniazid more than 40 years after its introduction in 1952. Today, it is known that the bioactivation of isoniazid is catalyzed by the mycobacterial catalase-peroxi-

dase called KatG. The generated reactive species form adducts with NAD⁺ and NADP⁺ that inhibit the biosynthesis of mycolic acid required for the mycobacterial cell wall (Timmins and Deretic, 2006). Sometimes, unintentionally developed prodrugs can reveal a less appealing truth of the drug under the development. A good example is heroin (diacetylmorphine), which was marketed during the years 1898 to 1910 as a nonaddictive morphine substitute to suppress cough and cure both cocaine and morphine addictions. Bayer was embarrassed to appreciate later that heroin is, in fact, rapidly metabolized into morphine after oral administration (Inturrisi et al., 1983; Sawynok, 1986).

Since the 1960s there has been an explosive increase in the use of prodrugs in drug discovery and development. The beginning of 21st century, when property-based drug design became an essential part of the drug discovery and development process (van De Waterbeemd et al., 2001), has been a time of real breakthroughs in prodrugs. This can be seen in published journal articles, reviews, and patents, as well as in numbers of clinically studied and marketed medicines. Moreover, dozens of prodrugs are currently undergoing clinical trials. To emphasize the extent of the successful

implementation of the prodrug approach, almost 15% of the 100 best-selling small-molecular-weight drugs in 2009 were prodrugs (Table 2) (Rautio, 2010). One interesting example of these blockbuster prodrugs is lisdexamfetamine dimesylate (Vyvanse), the L-lysine prodrug of the psychostimulant dextroamphetamine, which was designed to have less abuse potential than other amphetamines due to the slower release of the active parent drug if inhaled or injected. Another best-selling group of prodrugs are the proton pump inhibitors (PPIs) omeprazole and its analogs, which are site-selectively bioactivated to their active species in the acidic parietal cells of stomach (also discussed in section III.E).

III. Rationale for Prodrug Design

The prodrug approach is a very versatile strategy to increase the utility of pharmacologically active compounds, because one can optimize any of the ADMET properties as well as prolong the commercial life cycle of potential drug candidates. In most cases, prodrugs contain an obvious carrier or promoiety, which will be removed by enzymatic or chemical reaction(s), whereas

some prodrugs release their active drugs after molecular modification (e.g., after oxidation or reduction reaction). The latter are usually referred to as bioprecursor prodrugs. Conventional carrier-linked prodrugs often have a synthetic handle, a spacer or linker, between the active drug and the promoiety when the desired prodrug moiety cannot be attached directly to the parent molecule because of steric hindrance or functional properties. The spacers are usually cleaved spontaneously after the enzymatic or chemical decomposition of the prodrug bond between the promoiety and spacer (Papot et al., 2002). The prodrug candidate can also be prepared as a double prodrug, where the second promoiety is attached to the first promoiety linked to the parent drug molecule. These promoieties are usually different and are cleaved by a dissimilar mechanism. The term double prodrug should not be confused with the term bifunctional prodrug, which means that the parent drug molecule has been modified at two functional groups of the parent molecule. In some cases, two pharmacologically active drugs can be coupled together in a single molecule, called a codrug. In a codrug each drug acts as a promo-

TABLE 2
The occurrence of prodrugs among the world's 100 top-selling pharmaceuticals in 2009

Prodrug Name (Trade Name) and Therapeutic Area	Functional Group	Prodrug Strategy
Proton pump inhibitors Esomeprazole (Nexium) Lansoprazole (Prevacid) Pantoprazole (Protonix) Rabeprazole (Aciphex)	Formation of active sulfonamide form	Bioprecursor prodrugs that are converted into their respective active sulfonamide forms site-selectively in acidic conditions of stomach
Antiplatelet agent Clopidogrel (Plavix)	Formation of the active thiol	Bioprecursor prodrug that selectively inhibits platelet aggregation
Antiviral agent Valacyclovir (Valtrex)	L-Valyl ester of acyclovir	Bioconversion by valacyclovir hydrolase (valacyclovirase) Transported predominantly by hPEPT1 Oral bioavailability improved from 12–20% (acyclovir) to 54% (valacyclovir)
Hypercholesterolemia Fenofibrate (Tricor)	Isopropyl ester of fenofibric acid	Lipophilic ester of fenofibric acid
Antiviral agent Tenofovir disoproxil (Atripla)	Bis-(isopropoxy-carbonyloxymethyl) ester of tenofovir	Bioconversion by esterases and phosphodiesterases The oral bioavailability of tenofovir from tenofovir disoproxil is 39% after food
Psychostimulant Lisdexamfetamine (Vyvanse)	L-Lysyl amide of dextroamphetamine	Bioconversion by intestinal or hepatic hydrolases Reduced potential for abuse due to prolonged release of active drug
Influenza Oseltamivir (Tamiflu)	Ethyl ester of oseltamivir carboxylate	Improved bioavailability compared with oseltamivir carboxylate, allowing oral administration
Hypertension Olmesartan medoxomil (Benicar)	Cyclic carbonate ester of olmesartan	Improved bioavailability compared with olmesartan, allowing oral administration
Immunosuppressant Mycophenolate mofetil (CellCept)	Morpholinyl ethyl ester of mycophenolic acid	Improved oral bioavailability with less variability
Glaucoma Latanoprost (Xalatan)	Isopropyl ester of latanoprost acid	Bioconversion by esterases Improved lipophilicity to achieve better ocular absorption and safety

ety for the other. In the following sections, the potential of the prodrug approach to improve unfavourable ADMET properties or to prolong the life cycle of drugs will be illustrated by providing several examples of clinically used and investigational prodrugs.

A. Improving Formulation and Administration

Dissolution of the drug molecule from the dosage form may be the rate-limiting step to absorption (Hörter and Dressman, 2001). In fact, achieving optimal solubility is one of the greatest challenges in the drug discovery process. It has been reported that more than 30% of drug discovery compounds have poor aqueous solubility (i.e., less than 10 μM) (Di and Kerns, 2007). Different formulation techniques, such as salt formation and solubilizing excipients, have been used to overcome this barrier. Prodrugs are an alternative way to increase the aqueous solubility of the parent drug molecule by improving dissolution rate via attached ionizable or polar neutral groups, such as phosphates, amino acids, or sugar moieties (Fleisher et al., 1996; Stella and Nti-Addae, 2007; Stella et al., 2007; Müller, 2009). These prodrugs can be used not only to enhance oral bioavailability but also to prepare parenteral or injectable drug delivery.

Phosphate esters are a widely used prodrug strategy for improving the aqueous solubility, not only oral but also and especially drugs intended for parenteral administration (Krise and Stella, 1996; Stella and Nti-Addae, 2007; Stella et al., 2007). The active parent drug molecule is rapidly released from phosphate prodrugs by endogenous phosphatases, such as alkaline phosphatase. This enzyme is particularly abundant on the brush border (or apical surface) of the enterocytes and in plasma. Because the phosphate group is cleaved before or during absorption after oral administration, the ionizable prodrug structure does not decrease the permeability of the parent drug molecule.

Prednisolone sodium phosphate (Pediapred; Fisons Corp., Bedford, MA) is a classic example of a phosphate

prodrug (Fig. 2). It is a highly water-soluble (>30 times greater than prednisolone), oral liquid formulation used as an immunosuppressant for children in allergic and inflammatory conditions and used to mask the unpalatable taste of prednisolone tablets. The phosphate moiety is linked directly to a free hydroxyl group on prednisolone, as is in the case with another well known oral phosphate prodrug, fosamprenavir (Lexiva, Telzir; Vertex Pharmaceuticals, Cambridge, MA) (see also section III.F). Amprenavir (Agenerase; Glaxo Group Ltd., Greenford, Middlesex, UK) is an HIV protease inhibitor that, because of its poor water solubility, was originally formulated in a capsule containing a high concentration of solubilizing excipients. To achieve the correct therapeutic concentration, patients had to take eight amprenavir capsules every day. By replacing amprenavir with its 10-fold more water-soluble prodrug fosamprenavir, one can achieve a simplified and patient-compliant dosage regimen (i.e., two tablets twice a day) that has the same therapeutic efficacy (Chapman et al., 2004; Furfine et al., 2004; Wire et al., 2006). Both of these orally administered phosphate prodrugs are rapidly hydrolyzed by gut epithelial alkaline phosphatases to their respective parent drugs during the absorption process, with only minimal concentrations of prodrugs reaching the circulation.

In another example, fosphenytoin sodium salt (Cerebyx; Warner-Lambert, Morris Plains, NJ), the phosphate ester is attached to an acidic amine of the antiepileptic agent phenytoin via an oxymethylene spacer (Fig. 2). Fosphenytoin is used to reduce drug precipitation and consequent local irritation by phenytoin at the injection site. It has an aqueous solubility more than 7000 times greater than that of phenytoin and is rapidly converted ($t_{1/2} < 15$ min in human) to phenytoin in blood (Unadkat and Rowland, 1985; Boucher, 1996; Browne et al., 1996). The enzymatic hydrolysis initially releases an unstable intermediate, which is spontaneously converted to phenytoin (Fig. 2).




FIG. 2. Bioactivation of phosphate prodrugs of prednisolone and phenytoin.

Amino acid esters or amides are also commonly used ionizable groups, which can be introduced into the hydroxyl, thiol, amine, or carboxylic acid functionalities of the parent drug molecule to compensate for poor aqueous solubility. A variety of esterases, amidases, and/or peptidases in plasma or in other tissues can bioconvert these prodrugs to their active counterparts. Quite often, however, amino acid ester and amide prodrugs suffer from poor aqueous stability or incomplete in vivo bioconversion, respectively, and therefore phosphate prodrugs are the preferred prodrug structures if one wishes to improve the aqueous solubility of the parent drug (Stella et al., 2007). Paradoxically, amino acid esters and amides can also be used to enhance absorption and consequently oral drug delivery of parent drugs, because the brush-border membrane of intestinal epithelium possesses a considerable number of transporters for amino acids and peptides (Majumdar et al., 2004; Dobson and Kell, 2008). Examples of these kinds of prodrugs will be given in the next chapter. Sugar moieties, such as glucose, galactose, or glucuronic acid, have also been used as ways to improve the aqueous solubility of poorly water-soluble drugs. These prodrugs are bioconverted to their parent drug molecules by β -glucosidase, β -galactosidase, or β -glucuronidase and usually have spacers between the parent drug and the promoiety (Leenders et al., 1999).

B. Enhancing Permeability and Absorption

The transport of a drug to its site of action usually requires passage through several lipid membranes; therefore, membrane permeability has a considerable influence on drug efficacy (Chan and Stewart, 1996). In oral drug delivery in particular, which is the preferred route for the majority of drugs, the most common absorption routes are unfacilitated and largely nonspecific, passive transport mechanisms. The lipophilicity of poorly permeable drugs can be increased by modifying the hydrocarbon moieties. However, good activity sometimes requires a structure, which is far from ideal one for good membrane permeability. In such situation, the prodrug strategy can be an extremely valuable option. Improvements of lipophilicity have been the most widely studied and therefore now also the most successful field of prodrug research. It has been achieved by masking polar ionized or nonionized functional groups to enhance either oral or topical absorption (e.g., for drugs to be given by transdermal and ocular administration) (Beaumont et al., 2003).

A hydrophilic hydroxyl, thiol, carboxyl, phosphate, or an amine group on the parent drug can be converted to more lipophilic alkyl or aryl esters, and these prodrugs are readily bioconverted to their active species by ubiquitous esterases, which are present throughout the body (Taylor, 1996; Liederer and Borchardt, 2006). The attractiveness of this prodrug approach is that the alkyl chain length can be modified to obtain precisely the

desired lipophilicity. Currently, a considerable number of ester prodrugs have advanced into clinical use.

Oseltamivir (Tamiflu; Hoffmann-La Roche Inc., Nutley, NJ) is an orally active ethyl ester prodrug of a selective inhibitor of viral neuraminidase glycoprotein and used in the treatment of influenza types A and B (Fig. 3). After absorption, oseltamivir undergoes rapid bioconversion to its parent drug mostly by the action of carboxylesterase (McClellan and Perry, 2001; Shi et al., 2006). The bioavailability of the more lipophilic oseltamivir is almost 80%, whereas the corresponding value for free carboxylate is as low as 5%. Likewise, adefovir dipivoxil (Hepsera; Gilead Sciences, Inc., Foster City, CA) represents a more recent example of a prodrug, in which the ester promoiety is attached to a phosphoryl group on the parent drug via a spacer (Fig. 3). This pivaloyloxymethyl phosphoric acid ester of the nucleotide reverse transcriptase inhibitor adefovir (PMEA) is given orally to treat retro-, herpes-, and hepadnaviruses and has almost four times greater bioavailability than adefovir itself (Benzaria et al., 1996; Noble and Goa, 1999).

The latest clinical example of a more lipophilic oral prodrug is dabigatran etexilate (Pradaxa; Boehringer Ingelheim Pharma GmbH, Ingelheim, Germany), a direct thrombin inhibitor for stroke prevention, which has been available in Europe and many other countries since 2008. However, it was not until the October 2010 when dabigatran etexilate became the first oral alternative to warfarin to be approved in the United States (Hughes, 2010). The active drug dabigatran is a very polar, permanently charged molecule with a log P of -2.4 (*n*-octanol/buffer, pH 7.4) and therefore it has zero bioavailability after oral administration (Eisert et al., 2010). In the more lipophilic bifunctional prodrug dabigatran etexilate, the two polar groups, the amidinium moiety and carboxylate, are masked by carbamic acid ester and carboxylic acid ester groups, respectively, which results in better absorption with bioavailability of 7% after oral administration (Stangier et al., 2007; Blech et al., 2008). Unlike its predecessor, the bifunctional prodrug ximelagatran [Exanta (AstraZeneca, Pharmaceuticals LP, Wilmington, DE); withdrawn from the market in 2006] (Sorbera et al., 2001), dabigatran etexilate has not shown any long-term adverse effects, such as liver toxicity.

Another method to increase oral absorption is to design prodrugs, which have structural features similar to substrates that are absorbed by carrier-mediated transport. This strategy is particularly important when passive transcellular absorption is negligible. Good examples of carrier-mediated of prodrugs are midodrine (ProAmatine, Gutron; Shire Llc, Florence, KY) and valacyclovir (Valtrex; SmithKline Beecham, Philadelphia, PA; Glaxo Wellcome Inc., Research Triangle Park, NC) (Fig. 4). Midodrine is a glycine prodrug of desglymidodrine [1-(2',5'-dimethoxyphenyl)-2-aminoethanol (DMAE)], a se-




FIG. 3. Bioactivation of ester prodrugs oseltamivir, adefovir dipivoxil, and dabigatran etexilate.

lective $\alpha 1$ -receptor agonist used in the treatment of orthostatic hypotension, in which the glycine promoiety is attached to an amine group of DMAE. Midodrine is absorbed via the intestinal proton-coupled peptide transporter 1 and is bioconverted by as-yet-unknown peptidases, mainly in the liver and systemic circulation (Cruz, 2000; Tsuda et al., 2006). It has an oral bioavailability of 93%, which is significantly more than the corresponding value for DMAE (50%).

Valacyclovir is a L-valyl ester prodrug of acyclovir, a purine nucleoside used for the treatment of herpes virus infections. Valacyclovir is a substrate, not only for peptide transporter 1 (Balimane et al., 1998; Sinko and Balimane, 1998) but also for Na^+ -dependent neutral amino acid transporter, $\text{ATB}^{0,+}$ (Ganapathy and Ganapathy, 2005). After absorption, it is bioactivated by valacyclovir hydrolase (Burnette et al., 1995). The bioavailability of this prodrug is more than 50%, which is 20 to 35% better than the bioavailability of acyclovir (Granero and Amidon, 2006). Valacyclovir is actually a

preprodrug or double prodrug, because after the hydrolysis of the valine promoiety, acyclovir, like all nucleosides, requires phosphorylation before it forms the active nucleotide triphosphate. The first phosphorylation reaction is mediated by viral thymidine kinase, which is far more effective than the endogenous enzyme in uninfected cells. This further improves the selectivity of acyclovir. Cellular kinases subsequently phosphorylate the nucleotide monophosphate to its active triphosphate form, which then can act as a selective inhibitor of viral DNA polymerase (Elion, 1983; Darby, 1993).

Prodrugs with lipophilic promoieties have also been used to improve topical absorption for transdermal and ocular drugs (Sloan and Wasdo, 2003; Sloan et al., 2006). The stratum corneum, the outermost layer of the epidermis, represents a high resistance barrier against topical drug delivery. Only the drugs with balance of both water and lipid solubilities can efficiently penetrate through the layers of the skin. These optimal features can be achieved by prodrug technology. Tazarotene (Tazorac;




FIG. 4. Bioactivation of amino acid prodrugs midodrine and valacyclovir.

Allergan, Inc., Irvine, CA) is an example of a marketed ethyl ester prodrug with enhanced transdermal drug delivery (Foster et al., 1998). Tazarotene is used for psoriasis and acne treatment and causes less skin irritation than the parent drug tazarotenic acid (Fig. 5). For more examples of investigational transdermally administered prodrugs, see the review by Fang and Leu (2006).

In the case of topically administered ophthalmic drugs, the corneal epithelium limits the permeation of

drugs into intraocular tissues. However, more lipophilic ester prodrugs as well as transporter-mediated amino acid prodrugs have improved ocular drug delivery with greatly reduced adverse effects, especially on the surface of the eye (Duvvuri et al., 2003, 2004). The first prodrug to improve ocular absorption was the dipivalyl diester of epinephrine (adrenaline), dipivefrin (Propine; Allergan, Inc.), introduced to the market over 15 years ago to lower the intraocular pressure in glaucoma (Fig. 5). Dip-




FIG. 5. Bioactivation of topically administered ester prodrugs tazarotene and dipivefrin.

D. Protecting from Rapid Metabolism and Excretion

Presystemic metabolism (the so-called first-pass effect) in the gastrointestinal tract and liver may greatly reduce the total amount of active drug reaching the systemic circulation and ultimately its target. This problem has been bypassed by sublingual or buccal administration or by modified or controlled release formulations. Rapid metabolic breakdown of the drug can also be protected by a prodrug structure. This is usually carried out by masking the metabolically labile but pharmacologically essential functional group(s) of the drug. In the case of the bronchodilator and β_2 -agonist terbutaline, sustained drug action has been achieved by converting its phenolic groups, which are susceptible to rapid and extensive presystemic metabolism, into bis-dimethylcarbamates (Fig. 7). This prodrug, bambuterol (Bambec, Oxeol; AstraZeneca Pharmaceuticals LP, Wilmington, DE), is slowly bioactivated to terbutaline predominantly by nonspecific butyrylcholinesterase mainly outside the lungs (Svensson and Tunek, 1988; Tunek et al., 1988; Sitar, 1996). As a result of the slower release and prolonged action, once-daily administration of bambuterol provides relief of asthma with a lower incidence of adverse effects than terbutaline, which needs to be taken three times a day (Persson et al., 1995).

In addition to metabolic pathways, the beneficial effects of drugs can be impaired as a result of extensive excretion. The kidneys, which are the principal organs of excretion, efficiently eliminate water-soluble substances from the body. Therefore, the use of lipophilic promoieties to decrease the solubility is one way to prolong the duration of action of very water-soluble drugs. Good examples of these prodrugs are anticancer and antiviral nucleoside phosphates and phosphonates, such as adefovir dipivoxil (see section III.B).

E. Overcoming Toxicity Problems

Adverse drug reactions can change the structure or function of cells, tissues, and organs and can be detrimental to the organism. Reduced toxicity can sometimes be accomplished by altering one or more of the ADME barriers discussed earlier but more often is achieved by






FIG. 7. Bioactivation of a carbamate prodrug of terbutalin.

targeting drugs to desired cells and tissues via site-selective drug delivery. A successful site-selective prodrug must be precisely transported to the site of action, where it should be selectively and quantitatively transformed into the active drug, which is retained in the target tissue to produce its therapeutic effect (Ettmayer et al., 2004; Stella et al., 2007). The ubiquitous distribution of most of the endogenous enzymes that are responsible for bioactivating prodrugs diminishes the opportunities for selective drug delivery and targeting. Therefore, exogenous enzymes selectively delivered via monoclonal antibodies (antibody-directed enzyme prodrug therapy) or as genes that encode prodrug activating enzymes in the target-specific nonviral or viral vectors (gene-directed enzyme prodrug therapy and virus-directed enzyme prodrug therapy) are widely used, especially with highly toxic compounds, such as anticancer drugs, to reduce the toxicity of the drugs at other sites in the body (Denny, 2001; Shanghag et al., 2006).

Cytochrome P450 enzymes (P450s) can be exploited for liver-targeted drug delivery, because these enzymes are present at the highest concentrations in hepatocytes. However, when targeting the P450 enzymes, special attention needs to be paid during the drug development process to potential species and patient related variations, genetic polymorphisms, as well as the potential for drug-drug interactions (Ettmayer et al., 2004) (see section IV.B). Despite the presence of numerous P450-activated prodrugs, only cyclic phosphate and phosphonate prodrugs, called HepDirect prodrugs, are liver-specific (Erion et al., 2004, 2005). Pradefovir was the first HepDirect prodrug that advanced to clinical trials. It was developed to improve the therapeutic potential of the adefovir dipivoxil (pivaloyloxymethyl phosphoric acid ester prodrug of PMEA; see section III.B), because the phase III clinical studies had revealed that the presence of PMEA in the kidneys and the subsequent kidney toxicity limited the use of adefovir dipivoxil (Dando and Plosker, 2003). In contrast, the HepDirect prodrug of PMEA (Fig. 8) displayed 12-fold higher liver/kidney and 84-fold higher liver/intestine targeting ratio relative to adefovir dipivoxil in vivo in rats (Reddy et al., 2005; Stella et al., 2007). Moreover, the prodrug has good therapeutic efficacy in patients with hepatitis B but still achieves low systemic adefovir levels. Although the non-clinical carcinogenicity studies revealed increased incidence of cancer at higher doses, pradefovir has com-

pleted the phase II clinical trials and its clinical development continues (Erion et al., 2006; Tillmann, 2007).

4-Amino-1-(5-*O*-(2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl)arabinofuranosyl)-2(1*H*)-pyrimidinone (MB07133), a cyclic phosphonate of the anticancer agent arabinofuranosyl cytidine [cytarabine (araC)], is another HepDirect prodrug currently undergoing clinical evaluation for the treatment of hepatocellular carcinoma (Fig. 8) (MacKenna et al., 2009). In vivo studies with rodents have shown that the araC triphosphate levels are over 19-fold greater in the liver than in plasma representing a 120-fold improvement over araC administration (Boyer et al., 2006). Furthermore, the initial data from the phase Ib clinical trial have indicated that MB07133 is well tolerated in patients with no overt effects on liver function (MacKenna et al., 2009). In both cases, the prodrug is bioactivated by CYP3A4-catalyzed hydroxylation that occurs selectively in the benzylic carbon atom adjacent to a phosph(on)ate oxygen. This results in irreversible ring opening and the formation of a transient intermediate. The anionic intermediate and the generated negatively charged phosphate have poor diffusion properties across cell membranes and are therefore retained in the hepatocytes, which augments their liver specificity.

Site-selective prodrug activation can also be achieved by exploiting the physiological conditions of the target tissue if that differs from conditions elsewhere in the body. Many solid tumors, for example, have selective enzyme expression, hypoxic cells, and lower extracellular pH (Denny, 2001). Hypoxia, the deficiency of oxygen as a result of an insufficient vasculature, imposes an environmental stress on the cells, which contributes to tumor progression, invasion, and metastasis. Moreover, a low oxygen content increases the resistance to radiotherapy and chemotherapy (Denny, 2010). However, the hypoxic state of solid tumors can be turned to a therapeutic advantage by designing cytotoxic prodrugs, which are bioactivated to their active species selectively in the hypoxic environment of solid tumors by endogenous reductive enzymes. Although these enzymes are also present in normal aerobic cells, the action of the cytotoxic species is limited to tumor cells, because the reduced prodrug intermediates are rapidly reoxidized back to the inactive prodrugs in healthy cells.

Tirapazamine (TPZ, SR 4233), a heteroaromatic *N*-oxide, is a well known example of a hypoxia-activated anticancer prodrug, which has served as a lead com-




FIG. 8. Bioactivation of cyclic phosphonate prodrugs pradefovir and MB07133.

pound in the development of a number of newer prodrugs with improved anticancer properties (Fig. 9). TPZ is bioactivated by a one-electron bioreduction, primarily by NADPH:cytochrome P450 reductase, to a highly DNA-reactive radical (Lloyd et al., 1991; Fitzsimmons et al., 1994; Patterson et al., 1995; Anderson et al., 2003) and has 50- to 200-fold hypoxic selectivity in cell suspension cultures (Zeman et al., 1986). Currently, TPZ is undergoing several phase I to III clinical trials in both single and combination therapies for lung and cervical cancers, as well as head and neck cancers. The gene-directed enzyme prodrug therapy approach has also been used to encode NADPH:CYP450 reductase within the hypoxic tumor cells to achieve enhanced TPZ activation (Cowen et al., 2004).

2-((2-Bromoethyl)-2-[(2-hydroxyethyl)amino]carbonyl)-4,6-dinitroanilino)ethyl methanesulfonate phosphate ester (PR-104) is another fairly recent example of a hypoxia-selective anticancer prodrug (Fig. 9). It is a bifunctional prodrug, because it has a phosphate ester promoiety to improve its aqueous solubility and nitroaromatic group as a hypoxia-selective promoiety. After phosphatase-cata-

lyzed hydroxylation of PR-104 to PR-104A, the dinitrobenzamide mustard is selectively bioreduced to the corresponding hydroxylamine (PR-104H) and amine (PR-104M), which are DNA-crosslinking species able to diffuse to a limited extent into extracellular environment and kill also neighboring cells (Hicks et al., 2007). One-electron bioreduction is catalyzed mainly by cytochrome NADPH:cytochrome P450 reductase (Guise et al., 2007), although in certain tumor cell lines, PR-104 is also known to be bioactivated by aldo-keto reductase 1C3 in the presence of oxygen (Guise et al., 2010). PR-104 is currently undergoing several phase I and II clinical trials in both single and combination therapies for solid tumors, lung cancer, and leukemia.

The widely used proton pump inhibitors (PPIs), such as omeprazole, represent examples of prodrugs that are site-selectively bioactivated to their active species in a unique pH environment. To protect these acid-labile prodrugs from rapid destruction within the gastric lumen, PPIs are formulated for delayed release as acid-resistant, enteric-coated tablets. After passing through the stomach into the alkaline intestinal lumen, the enteric




FIG. 9. Bioactivation of hypoxia-activated prodrugs tirapazamine and PR-104.

coatings dissolve, and the prodrug is absorbed (Missaghi et al., 2010). Because omeprazole is a basic molecule (pK_a of 3.97), it accumulates in the acidic secretory parietal cells after protonation of its pyridyl group (Sachs et al., 1995). Omeprazole is then converted to its active sulfonamide in the acidic conditions of parietal cells, which then binds irreversibly to a cysteine group in the gastric H^+/K^+ ATPase (Fig. 10). This subsequently prevents the parietal cells from producing and secreting gastric acid (Shin et al., 2004). The favorable safety

profile of omeprazole exists because nongastric H^+/K^+ ATPases lack the highly acidic compartment that is present in the parietal cells and are thus unable to convert omeprazole into its active form. Other PPIs are bioactivated by a similar mechanism as omeprazole.

F. Managing the Life Cycle

If the prodrug structure of an existing drug has not been described previously in the literature, it can be considered a new chemical entity and therefore receive




FIG. 10. Bioactivation of omeprazole in acidic conditions.

intellectual property protection against unauthorized competition during its development and commercialization. Because the development of a prodrug can be less expensive and faster than optimizing the therapeutic activity and ADME properties of a novel drug candidate at the same time, prodrugs can offer a valuable opportunity to improve the life-cycle management of the parent drug. Fosamprenavir, the water-soluble prodrug developed by GlaxoSmithKline (see section III.A), represents an excellent example of a prodrug with improved life-cycle management (Fig. 11). This phosphate ester of the HIV protease inhibitor amprenavir was originally designed to improve solubility and oral bioavailability (Chapman et al., 2004; Furfine et al., 2004; Wire et al., 2006). However, at the same time, this prodrug will continue the life cycle of amprenavir, because the fosamprenavir patent will last until 2017, whereas the patent on amprenavir will expire in 2013. Therefore, it is very likely that the additional costs that were consumed in the development of fosamprenavir will be fully covered by its extended patent duration (Stella et al., 2007).

IV. Preclinical and Clinical Considerations of Prodrug Bioconversion

Prodrug strategies have arguably been successful for a number of clinically used therapeutic agents. However, prodrug research encounters various challenges and additional work in preclinical and clinical settings, much of which can be attributed to understanding the bioconversion mechanisms of prodrugs. Many enzymes involved in prodrug activation are subject to interindividual variabilities in their activities. The main factors contributing to this variability are intrinsic, especially polymorphisms in the genes encoding the enzymes, but can also be extrinsic (i.e., interactions caused by other drugs and xenobiotics). Both intrinsic and extrinsic factors may cause insufficient or excessive conversion of the prodrugs into their active forms. Moreover, interspecies differences in enzyme activation represent another hurdle to the prediction of human disposition of certain prodrugs. This section focuses on esterases and P450 enzymes, which are particularly widely exploited enzymes in prodrug research.

A. Esterase-Catalyzed Hydrolysis of Prodrugs

The most common approaches for prodrug design are aimed at prodrugs undergoing metabolic bioconversion to the active parent drug by functionally prominent and

diversity-tolerant hydrolases such as peptidases, phosphatases, and (in particular) carboxylesterases (Beaumont et al., 2003). Because they are ubiquitously distributed, the potential for carboxylesterases to become saturated or the potential for their substrates to become involved in drug-drug interactions is generally considered to be negligible (Liederer and Borchardt, 2006) although not impossible (Bellott et al., 2008).

The majority of carboxylesterases can be found in two isozyme families, CES1 and CES2, which are characterized by their substrate specificities, tissue distribution, and gene regulation. In humans, CES1 is highly expressed in the liver, but can be also detected in other tissues, with the notable exception of the intestine. Human CES2, however, is highly expressed throughout the intestine and kidney, although at much lower levels than CES1 in the liver (Satoh and Hosokawa, 2006). The differences in both localization of CES1 and CES2 in humans and their substrate specificities can be taken into account in prodrug design. In general, CES1 prefers the hydrolysis of esters with large acyl and small alcohol groups, whereas CES2 hydrolyzes esters of smaller acyl and larger alcohol groups (Satoh et al., 2002). Therefore, CES1 can hydrolyze, for example, temocapril, with its small alcohol group and large acyl group, with a higher efficiency than CES2, which, on the other hand, is the enzyme almost exclusively hydrolyzing drugs such as irinotecan and heroin, with their bulky alcohol groups (Fig. 12).

Although being an attractive target for various prodrugs, interspecies differences in esterase expression make it difficult to translate preclinical data in humans. For example, there is minimal hydrolase activity in small intestine of dog, but rodent species frequently have higher hydrolase activity in plasma than humans (Imai, 2006). Moreover, screening for the effects of hydrolase activated prodrugs in colon carcinoma tissue (e.g., Caco-2 monolayers) may be somewhat misleading due to differences between carboxylesterase expression in colon carcinoma and the adjacent normal tissues (Imai et al., 2005). Using human recombinant enzymes or human tissue extracts, however, can reduce the interspecies variability and help to identify tissue specific hydrolysis.

The less than complete absorption observed with several hydrolase-activated prodrugs of penicillins, cephalosporins, and angiotensin-converting enzyme inhibitors highlights yet another challenge with prodrugs suscep-




FIG. 11. Bioactivation of a phosphate prodrug of amprenavir.




FIG. 12. Bioactivation of ester prodrugs temocapril and irinotecan.

tible to esterase hydrolysis. These prodrugs typically have bioavailabilities of around 50% because of their premature hydrolysis during the absorption process in the enterocytes of the gastrointestinal tract (Beaumont et al., 2003). Hydrolysis inside the enterocytes releases the active parent drug, which in most cases is more polar and less permeable than the prodrug, and which is more likely to be effluxed by passive and carrier-mediated processes back into the lumen than to proceed into blood, therefore limiting oral bioavailability.

Finally, although more studies are needed to understand whether polymorphisms of CES genes can have a major impact on the clinical variability of certain prodrugs, scattered evidence from several reports indicates that CES variants can indeed cause variable systemic exposure; this has been observed with prodrugs such as angiotensin-converting enzyme inhibitors, as well as capecitabine and irinotecan (Bai et al., 2010).

B. Prodrug Bioactivation by Cytochrome P450 Enzymes

The P450 enzymes are a superfamily enzymes accounting for up to 75% of all enzymatic metabolism of drugs, including several prodrugs. There is accumulating evidence that genetic polymorphisms of prodrug-activating P450s contribute substantially to the variability in prodrug activation and thus to efficacy and safety of drugs using this bioactivation pathway (Gonzalez and Tukey, 2006; Testa and Kramer, 2007). Several drug-metabolizing P450 genes are known to be polymorphic, including *CYP2A6*, *CYP2B6*, *CYP2C9*, *CYP2C19*, and *CYP2D6*. In particular, the *CYP2D6* gene is highly polymorphic, with 75 different major alleles currently known. Some of these alleles are associated with reduced enzyme activity or even the absence of enzyme function (Krämer and Testa, 2008). On the basis of the combination of *CYP2D6* alleles, persons can be categorized into three main genotypes: poor metabolizers

(PMs), extensive metabolizers (EMs), and ultrarapid metabolizers (Table 3). All of the variant P540 alleles are described by the Human Cytochrome P540 Allele Nomenclature Committee (<http://www.cypalleles.ki.se/>).

On the other hand, there are numerous cases of drug interactions causing altered activation of prodrugs with deleterious clinical consequences. A drug interaction occurs when the effects of a drug are markedly altered as a result of coadministration of another drug. Drug interactions may be pharmacokinetic, pharmacodynamic, or a combination of the two. Pharmacokinetic interactions result in increased or decreased delivery of drugs to the sites of action. Metabolic drug interactions may occur during the phase I or II biotransformation reactions. They are mainly based on inhibition or induction of the metabolic enzymes. Drug metabolism may be considered in four different outcomes: 1) an active parent substrate forms an inactive metabolite, 2) an active substrate forms an active metabolite, 3) an inactive substrate (prodrug) forms an active compound, or 4) a parent compound is transformed into toxic metabolites. P450s are the main enzymes in drug metabolism and thus the main mediators of metabolic drug interactions.

This section will describe several examples in which genetic polymorphisms of P450 enzymes and drug interactions have been shown to influence the systemic exposure and response to prodrugs. Certain anticancer drugs,

TABLE 3
Simplified genotype-phenotype relationship for *CYP2D6*

Genotype (Allele Combination)	Phenotype
(wt/wt) _n ^a	UM
wt/wt	EM
wt/*x	EM
*x/*x	PM

wt, active wild-type; UM, ultrarapid metabolizer; *x, inactive.
^a n ≥ 2.

drugs for cardiovascular diseases, and opioid analgesics are highlighted.

1. Anticancer Drugs. Oxazaphosphorines, including cyclophosphamide, ifosfamide, and trofosfamide, are prodrugs used for treating different types of cancers and autoimmune diseases. The bioconversion of these cyclic phosphate drugs to the corresponding cytotoxic species is initiated by P450 enzymes. Many different P450 enzymes participate in the hydroxylation of a carbon-4 of the oxazaphosphorine ring. The unstable intermediates formed decompose to the corresponding aldehydes, which are degraded further to active nitrogen mustard derivatives (Fig. 13).

Several P450 enzymes, including CYP2B6, CYP3A4, and CYP2C19, have been implicated in the activation of cyclophosphamide to its active metabolites 4-hydroxycyclophosphamide and aldophosphamide. The use of oxazaphosphorines can be associated with severe toxicity, because their metabolism leads to the formation of the highly reactive metabolite acrolein, which is responsible for urotoxicity, neurotoxicity, and nephrotoxicity (Huttunen et al., 2008; Giraud et al., 2010). *CYP2B6* and *CYP2C19* are highly polymorphic, such that some of their variant alleles have reduced or no activity compared with the wild-type allele. These and other genetic factors are thought to play a role in the interindividual variation in both response and toxicity associated with cyclophosphamide-based therapies (Pinto et al., 2009).

Tegafur is a prodrug has been used clinically for almost 30 years in the treatment of several common tumors. Tegafur is activated by P450 enzymes, via hydroxylation, to 5-fluorouracil (5-FU) (Fig. 14). 5-FU inhibits thymidylate synthase and is incorporated into DNA and/or RNA. The NADPH-dependent P450-catalyzed hydroxylation of the furan ring produces an intermediate that spontaneously decomposes to the active 5-FU and the succinic aldehyde moiety. *CYP2A6* is the principal enzyme responsible for the activation of tegafur in human liver microsomes, but *CYP1A2*, *CYP2C8*, and thymidine phosphorylase also contribute to this process (Huttunen et al., 2008). Several clinical studies have indicated that systemic exposure to tegafur is in-




FIG. 14. Bioactivation of tegafur.

creased in patients with *CYP2A6* PM genotype, caused either by deletion of the *CYP2A6* gene or the presence of inactive alleles, leading to reduced enzyme activity (Bai et al., 2010).

Tamoxifen is a synthetic antiestrogen widely used for breast cancer therapy and even as a prophylactic agent in healthy women who carry a high risk of contracting breast cancer. Treatment with tamoxifen can reduce the incidence of breast cancer in these high-risk women by almost half. It also reduces by almost 30% the annual risk of death when administered after surgery for invasive breast cancer. In vitro studies have demonstrated that tamoxifen itself has very little affinity for its biological target, the estrogen receptor in breast tissue (Jordan, 2007). As shown in Fig. 15, to exert its antiestrogenic effects in breast, tamoxifen must first be metabolized in the liver by P450 enzymes to two active metabolites, 4-hydroxytamoxifen and 4-hydroxy-*N*-desmethyltamoxifen (endoxifen). Endoxifen is present at concentrations up to 20-fold higher than 4-hydroxytamoxifen and is pharmacologically distinct from either tamoxifen or 4-hydroxytamoxifen.

Several different P450 forms may be involved in catalyzing the *N*-demethylation of tamoxifen. The *CYP2D6* enzyme is responsible for the oxidation of the most abundant tamoxifen metabolite, *N*-desmethyltamoxifen, to




FIG. 15. Bioactivation of tamoxifen.




FIG. 13. Bioactivation of oxazaphosphorine prodrugs.

endoxifen (Jordan, 2007; Huttunen et al., 2008; Sideras et al., 2010). Considerable mechanistic, pharmacologic, and clinical pharmacogenetic evidence supports the concept that CYP2D6 genetic variants and phenocopying effects through drug interactions with CYP2D6 inhibitors can influence plasma concentrations of active tamoxifen metabolites and negatively affect the therapeutic outcome. Women with genetically normal CYP2D6 function have been shown to benefit more from tamoxifen therapy than women who have deficient activity (Brauch and Jordan, 2009). On the basis of these findings, the United States Food and Drug Administration (FDA) Advisory Committee for Pharmaceutical Science in 2006 recommended a label change to include information that CYP2D6 is an important pathway in the formation of endoxifen and that postmenopausal women with estrogen receptor-positive breast cancer who are CYP2D6 PMs, either by genotype or because of drug interactions, are at increased risk for breast cancer recurrence (United States Food and Drug Administration, 2006).

Drugs that inhibit CYP2D6 activity can also affect the concentrations of active tamoxifen metabolites. For example, tamoxifen-treated extensive metabolizers who are coprescribed potent CYP2D6 inhibitors such as paroxetine or fluoxetine displayed endoxifen concentrations similar to patients with the PM CYP2D6 genotype. Several other drugs are known to inhibit CYP2D6 and could in theory lead to insufficient activation of tamoxifen. However, prospective clinical studies addressing this issue thus far are lacking. A recent review recommended that potent CYP2D6 inhibitors should be avoided in women receiving tamoxifen (Sideras et al., 2010).

2. Cardiovascular Drugs. Losartan is an angiotensin II type 1 receptor antagonist used as for the treatment of hypertension and other cardiovascular diseases. After oral administration, approximately 14% of the losartan dose is converted to the pharmacologically active metabolite called EXP3174 [2-*n*-butyl-4-chloro-1-((2'-(1*H*-tetrazol-5-yl)biphenyl-4-yl)methyl)imidazole-5-carboxylic acid] (Fig. 16). EXP3174 is 10- to 40-fold more potent than losartan and has a longer duration of action. The major metabolic pathway for losartan is through CYP2C9 with some contribution from CYP3A4 (Sica et al., 2005). In patients with the CYP2C9 PM genotype,

the metabolism of losartan to EXP3174 and its hypotensive effect are significantly reduced (Sekino et al., 2003).

In healthy volunteers, concomitant use of the CYP2C9 inhibitors fluconazole and buconazole has been shown to prevent the formation of the active metabolite in healthy volunteers (Kaukonen et al., 1998; Kobayashi et al., 2008). A pharmacoepidemiologic study (Tirkkonen and Laine, 2004) indicated that in hospitalized patients, losartan is often used with drugs that inhibit CYP2C9 (19% of all losartan treatment periods). In an attempt to overcome these problems, a novel prodrug of the active metabolite EXP3174 was developed (EXP3174-pivoxil). Initial pharmacokinetic characterization showed that it could be administered at a lower dose than losartan, and it also achieved a more rapid and more consistent therapeutic response compared with that of losartan (Yan et al., 2010).

Statins are HMG-CoA reductase inhibitors used in treatment of dyslipidemias. They are effective in both the primary and secondary prevention of atherosclerotic heart disease. These drugs lower the low-density lipoprotein (LDL) cholesterol concentrations in plasma by blocking cholesterol biosynthesis in the liver, which leads to an increase in the LDL clearance and an up-regulation of LDL receptors. They also decrease very-low-density lipoprotein cholesterol and triglyceride concentrations and increase high-density lipoprotein cholesterol levels slightly. In particular, the reduction in plasma levels of LDL cholesterol diminishes the risk for major cardiovascular events (Delahoy et al., 2009).

Because lovastatin and simvastatin are lactone prodrug forms, they are less active than the respective β -hydroxy acid metabolites (Fig. 17). Both parent drugs undergo extensive first-pass metabolism. Lovastatin is oxidized mainly by CYP3A4 to three known primary metabolites: 6' β -hydroxylovastatin, 6'-exomethylene metabolite, and 3'' β -hydroxylovastatin. All these metabolites are pharmacologically active. It is probable that the first two compounds derive from a single metabolic intermediate. Simvastatin is metabolized to at least four primary metabolites: 6' β -hydroxysimvastatin, 6'-exomethylene metabolite (which may derive from a common metabolic precursor), 6' β -hydroxymethyl metabolite, and 3'-hydroxysimvastatin (Fig. 17) (Neuvonen et al., 2008).

CYP3A4 inhibitors (e.g., clarithromycin, erythromycin, telithromycin, itraconazole, ketoconazole, diltiazem, and verapamil) have been shown to increase the exposure and toxicity of lovastatin and simvastatin. The increase in plasma concentrations can be up to 20-fold. Because they have such marked effects on the statin plasma concentration, these kinds of drug interactions increase the incidence of skeletal muscle toxicity, an adverse drug reaction concerning the entire class of statins, as well as the risk of potentially fatal rhabdomyolysis. On the other hand, the potent CYP3A4 inducers




FIG. 16. Bioactivation of losartan.




FIG. 17. Bioactivation of lovastatin and simvastatin.

rifampicin and carbamazepine have been shown to reduce simvastatin concentrations (Neuvonen, 2010).

A few pharmacoepidemiologic studies have attempted to assess the clinical consequences of interactions between lovastatin or simvastatin and CYP3A4 inhibitors or inducers. The risk of developing myopathy during

concomitant simvastatin and CYP3A4 inhibitor treatment was increased 9.1-fold over a low baseline incidence of 0.025% (Gruer et al., 1999). A later study (Tirkkonen et al., 2008) showed that 8.8 and 3.9% of hospital inpatients had received lovastatin or simvastatin concomitantly with a CYP3A4 inhibitor or inducer drug,

respectively. However, no major effect was observed on serum lipid concentrations or creatinine kinase activity. This lack of clinical effect is explained at least in part by the low doses of lovastatin and simvastatin taken by the patients in this study. It thus seems that lovastatin and simvastatin can be used rather safely with CYP3A4 inhibitors if the statin doses are low and the patients are monitored carefully.

Clopidogrel is an antithrombotic drug belonging to the thienopyridine group. The addition of clopidogrel to aspirin achieved significant reductions in major cardiovascular events in patients with acute coronary syndrome in general and particularly among those treated invasively by percutaneous coronary intervention. A barrier to clopidogrel absorption in the duodenum is its active intestinal transport by the P-glycoprotein efflux pump (ABCB1). Upon absorption, approximately 85% of the dose is hydrolyzed by esterases to an inactive carboxylic acid derivative. Multiple P450 isoforms metabolize the thiophene ring of the remaining 15% to produce the intermediate 2-oxoclopidogrel, which is then further metabolized to the pharmacologically active metabolite (Fig. 18). Upon release into the systemic circulation, the active metabolite's thiol group forms an irreversible disulfide bond with the platelet ADP P2Y₁₂ receptor (P2RY₁₂), altering its shape to prevent ADP-mediated platelet activation. Consequently, activation of the glycoprotein IIb/IIIa receptor, which binds fibrinogen and initiates platelet aggregation, is inhibited. Although multiple P450 isoforms can catalyze the conversion of clopidogrel to its active metabolite in vitro, CYP2C19 seems to be the primary P450 enzyme responsible for the bioactivation of clopidogrel in humans (Wallentin, 2009; Farid et al., 2010).

Numerous genes are involved in clopidogrel pharmacokinetics and pharmacodynamics, and the potential contribution of functionally relevant polymorphisms in these genes to the interindividual variability in clopidogrel response has been evaluated in a series of recent studies. Several studies have reported that, compared with wild type, CYP2C19 PM allele carriers exhibit a significantly lower capacity to metabolize clopidogrel into its active metabolite and inhibit platelet activation. Therefore, the poor metabolizers are at significantly higher risk of suffering adverse cardiovascular events, such as myocardial infarction, stent thrombosis, and death. Many studies have demonstrated a consistent association between CYP2C19 genotype, clopidogrel

pharmacokinetics, and clopidogrel pharmacodynamics in multiple populations, suggesting that the CYP2C19 genotype may be an important predictor of clinical response to clopidogrel (Ellis et al., 2009).

A recent meta-analysis revealed that the hazard is particularly increased among patients undergoing percutaneous coronary intervention for acute coronary syndrome and who carry a CYP2C19 PM allele (Mega et al., 2010). However, confirmation of this finding in larger trials powered to evaluate clinical outcome, which will ultimately be necessary. In March 2010, the FDA approved a new label for clopidogrel with a "boxed warning" describing the diminished effectiveness of the standard drug dosing in persons with impaired metabolic function based on their CYP2C19 genotype. The warning also notes that tests are available to identify patients with genetic polymorphisms and that alternative treatment strategies, either higher clopidogrel dosing regimens or the use of other antiplatelet agents, should be considered in those patients (Holmes et al., 2010).

CYP2C19 is responsible for the metabolism and clearance of many different drugs, including phenytoin, diazepam, proguanil, citalopram, venlafaxine, cyclophosphamide, and the proton pump inhibitors. Because of the increased risk for gastrointestinal tract bleeding associated with concomitant aspirin and clopidogrel antiplatelet therapy, PPIs are often administered to decrease risk of bleeding. Several recent studies have indicated that concomitant PPI therapy could be a possible contributor to clopidogrel nonresponsiveness, presumably via inhibition of the CYP2C19-mediated conversion of clopidogrel to its active metabolite. In addition to being well characterized substrates for CYP2C19, the PPIs are also potent competitive inhibitors of CYP2C19 metabolic activity in vitro (lansoprazole > omeprazole = esomeprazole > rabeprazole > pantoprazole), with pantoprazole having the least potent CYP2C19 inhibitory capacity (Ellis et al., 2009).

In May 2009, the European Medicines Agency issued a public statement on the putative interaction between clopidogrel and PPIs (Wathion, 2009). The Agency recommended that the product information for all clopidogrel-containing medicines should be amended to discourage concomitant use of PPIs and clopidogrel-containing medicines unless necessary. Furthermore, the Agency recommended that more information is needed in relation to the inhibition of clopidogrel metabolism by




FIG. 18. Bioactivation of clopidogrel.

other medicines and in relation to the implications of CYP2C19 genetic variation.

Very recent data (Bouman et al., 2011) obtained with in vitro liver microsomal assays confirmed the participation of multiple P450 forms (but curiously not CYP2C19) in the first step of clopidogrel activation. In addition, there was evidence that paraoxonase 1, an esterase associated with high-density lipoprotein concentrations in the blood, may be the rate-limiting enzyme for the second step of hydrolytic cleavage of the 2-oxoclopidogrel ring to the thiol active metabolite. Thus, the relative contribution of paraoxonase 1-mediated and oxidative P450-dependent ring cleavage needs to be elucidated before mechanistic interpretation to the epidemiological findings can be given.

3. Opioid Analgesics. Opiates are the cornerstone of the management of cancer pain and postoperative pain and are used increasingly for the management of chronic noncancer pain. Codeine and tramadol are weak opioid analgesics, and they are both prodrugs. It has been long known that codeine (methyldorphine) is converted into morphine by CYP2D6 (Fig. 19). The O-demethylation is essential for analgesia, because codeine itself has very low affinity for the opioid receptors. The CYP2D6 inhibitor quinidine has been shown to minimize the analgesic effect but also to reduce codeine abuse. In addition, the threshold of experimental pain by codeine is increased in CYP2D6 EMs but not in PMs, who lack the activation machinery. However, evidence for impaired analgesic outcome in CYP2D6 PMs is sparse, and it has been postulated that large-scale studies will be needed to demonstrate genetically determined unresponsiveness to codeine analgesia (Smith, 2009; Stamer et al., 2010).

On the other hand, subjects carrying a gene duplication or multiduplication may experience exaggerated pharmacologic effects in response to regular doses of

codeine. Enhanced CYP2D6 activity in these genotypes can predispose to life-threatening opioid intoxication. Several recent case reports of codeine fatalities highlighted that the use of this weak opioid, particularly in young children, could be attributed to their metabolic profile, especially in subjects displaying the ultrarapid metabolizer genotype (Gasche et al., 2004; Voronov et al., 2007; Ciszewski et al., 2009).

Tramadol is a codeine analog with weak μ -opioid receptor affinity. It is used as a racemic mixture. The (+)-enantiomer binds to the μ -receptor but also increases serotonin activity; the (–)-enantiomer stimulates α_2 -adrenergic receptors and inhibits noradrenaline reuptake. Thus, it is believed that at least part of the analgesic effect of tramadol is due to its ability to increase noradrenaline and serotonin activity. Like codeine, tramadol requires CYP2D6-mediated metabolism to an active metabolite, O-desmethyltramadol (M1), to be fully effective (Fig. 19) (Smith, 2009). Studies in healthy subjects have demonstrated that serum concentrations of M1 are lower in PMs than EMs. Thus, PMs lacking CYP2D6 activity demanded and received more tramadol doses via patient-controlled analgesia compared with patients with normal catalytic CYP2D6 activity. Prospective clinical studies have demonstrated that the analgesic effect of tramadol is linked to CYP2D6 genotype. In one study, the proportion of tramadol non-responders was increased in the CYP2D6 PM group compared with the patients with functionally active CYP2D6 alleles. Thus, there is evidence that CYP2D6 polymorphisms can influence the efficacy of codeine and tramadol analgesia, although in most trials, only a limited number of patients have been monitored (Stamer et al., 2010).

V. Conclusions

Biodegradable prodrugs can offer an attractive alternative to improve undesirable ADMET properties of a wide variety of drugs without losing the benefits of the drug molecule. Because of its versatility, the prodrug approach has enhanced the clinical usefulness of many pharmacological agents in the past, and as many as 10% of all approved small molecular drugs on the market today can be classified as prodrugs. However, the design of prodrugs should be considered at very early stages of the drug research and development process, because changing the ADMET properties may expose other undesired properties of the drug candidates. Bioconversion of prodrugs is perhaps the most vulnerable link in the chain, because there are a great many intrinsic and extrinsic factors that can influence the bioconversion mechanisms. For example, the activity of many of pro-drug activating enzymes may be decreased or increased due to genetic polymorphisms, age-related physiological changes, or drug interactions, leading to adverse pharmacokinetic, pharmacodynamic, and clinical effects. In




FIG. 19. Bioactivation of codeine and tramadol.

addition, there are wide interspecies variations in both the expression and function of the major enzyme systems activating prodrugs, and these can pose challenges in the preclinical optimization phase. Nonetheless, developing a prodrug can still be more feasible and faster strategy than searching for an entirely new therapeutically active agent with suitable ADMET properties.

Acknowledgments

This work was supported by the Academy of Finland [Grants 135439 (to K.M.H.), 132637 (to J.R.)]; and the Finnish Cultural Foundation (to K.M.H.).

Authorship Contributions

Wrote or contributed to the writing of the manuscript: Huttunen, Raunio, and Rautio.

References

Albert A (1958) Chemical aspects of selective toxicity. *Nature* **182**:421–422.

Anderson RF, Shinde SS, Hay MP, Gamage SA, and Denny WA (2003) Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. *J Am Chem Soc* **125**:748–756.

Bai JPF, Pacanowski M, Rahman A and Lesko LL (2010) The impact of pharmacogenetics on the clinical outcomes of prodrugs, in *Prodrugs and Targeted Delivery: Towards Better ADME Properties* (Rautio J ed) pp 453–481, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Balimane PV, Tamai I, Guo A, Nakanishi T, Kitada H, Leibach FH, Tsuji A, and Sinko PJ (1998) Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. *Biochem Biophys Res Commun* **250**:246–251.

Beaumont K, Webster R, Gardner I, and Dack K (2003) Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. *Curr Drug Metab* **4**:461–485.

Bellott R, Le Morvan V, Charasson V, Laurand A, Colotte M, Zanger UM, Klein K, Smith D, Bonnet J, and Robert J (2008) Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene. *Cancer Chemother Pharmacol* **61**:481–488.

Bentley R (2009) Different roads to discovery; Prontosil (hence sulfa drugs) and penicillin (hence beta-lactams). *J Ind Microbiol Biotechnol* **36**:775–786.

Benzarria S, Pelicano H, Johnson R, Maury G, Imbach JL, Aubertin AM, Obert G, and Gosselin G (1996) Synthesis, in vitro antiviral evaluation, and stability studies of bis-(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability. *J Med Chem* **39**:4958–4965.

Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, and Roth W (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. *Drug Metab Dispos* **36**:386–399.

Boucher BA (1996) Fosphenytoin: a novel phenytoin prodrug. *Pharmacotherapy* **16**:777–791.

Bouman HJ, Schömig E, van Werkum JW, Velder J, Hackeng CM, Hirschhäuser C, Waldmann C, Schmalz HG, ten Berg JM, and Taubert D (2011) Paraoxonase-1 is a major determinant of clopidogrel efficacy. *Nat Med* **17**:110–116.

Boyer SH, Sun Z, Jiang H, Esterbrook J, Gómez-Galeno JE, Craig W, Reddy KR, Ugarkar BG, MacKenna DA, and Erion MD (2006) Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1- β -D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma. *J Med Chem* **49**:7711–7720.

Brauch H and Jordan VC (2009) Targeting of tamoxifen to enhance antitumor action for the treatment and prevention of breast cancer: the ‘personalised’ approach? *Eur J Cancer* **45**:2274–2283.

Browne TR, Kugler AR, and Eldon MA (1996) Pharmacology and pharmacokinetics of fosphenytoin. *Neurology* **46**:S3–7.

Burnette TC, Harrington JA, Reardon JE, Merrill BM, and de Miranda P (1995) Purification and characterization of a rat liver enzyme that hydrolyzes valacyclovir, the L-valyl ester prodrug of acyclovir. *J Biol Chem* **270**:15827–15831.

Chan OH and Stewart BH (1996) Physicochemical and drug-delivery considerations for oral drug bioavailability. *Drug Discov Today* **1**:461–473.

Chapman TM, Plosker GL, and Perry CM (2004) Fosamprenavir: a review of its use in the management of antiretroviral therapy-naïve patients with HIV infection. *Drugs* **64**:2101–2124.

Ciszewski C, Madadi P, Phillips MS, Lauwers AE, and Koren G (2009) Codeine, ultrarapid-metabolism genotype, and postoperative death. *N Engl J Med* **361**:827–828.

Cowen RL, Williams KJ, Chinje EC, Jaffar M, Sheppard FC, Telfer BA, Wind NS, and Stratford IJ (2004) Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. *Cancer Res* **64**:1396–1402.

Cruz DN (2000) Midodrine: a selective alpha-adrenergic agonist for orthostatic hypotension and dialysis hypotension. *Expert Opin Pharmacother* **1**:835–840.

Dando T and Plosker G (2003) Adefovir dipivoxil: a review of its use in chronic hepatitis B. *Drugs* **63**:2215–2234.

Darby G (1993) The acyclovir legacy: its contribution to antiviral drug discovery. *J Med Virol Suppl* **1**:134–138.

del Amo EM, Urtti A, and Yliperttula M (2008) Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. *Eur J Pharm Sci* **35**:161–174.

Delahoy PJ, Magliano DJ, Webb K, Grobler M, and Liew D (2009) The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. *Clin Ther* **31**:236–244.

Denny WA (2001) Prodrug strategies in cancer therapy. *Eur J Med Chem* **36**:577–595.

Denny WA (2010) Hypoxia-activated prodrugs in cancer therapy: progress to the clinic. *Future Oncol* **6**:419–428.

Di L and Kerns EH (2007) Solubility issues in early discovery and HTS, in *Solvent Systems and Their Selection in Pharmaceuticals and Biopharmaceuticals* (Augustijns P and Brewster M eds) pp 111–136, Springer Science + Business Media, New York.

Dobson PD and Kell DB (2008) Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? *Nat Rev Drug Discov* **7**:205–220.

Duvvuri S, Majumdar S, and Mitra AK (2003) Drug delivery to the retina: challenges and opportunities. *Expert Opin Biol Ther* **3**:45–56.

Duvvuri S, Majumdar S, and Mitra AK (2004) Role of metabolism in ocular drug delivery. *Curr Drug Metab* **5**:507–515.

Eisert WG, Huel N, Stangier J, Wienen W, Clemens A, and van Ryn J (2010) Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. *Arterioscler Thromb Vasc Biol* **30**:1885–1889.

Elion GB (1983) The biochemistry and mechanism of action of acyclovir. *J Antimicrob Chemother* **12 Suppl B**:9–17.

Ellis KJ, Stouffer GA, McLeod HL, and Lee CR (2009) Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. *Pharmacogenomics* **10**:1799.

Erion MD, Bullough DA, Lin CC, and Hong Z (2006) HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver. *Curr Opin Investig Drugs* **7**:109–117.

Erion MD, Reddy KR, Boyer SH, Matelich MC, Gomez-Galeno J, Lemus RH, Ugarkar BG, Colby TJ, Schanzer J, and Van Poelje PD (2004) Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. *J Am Chem Soc* **126**:5154–5163.

Erion MD, van Poelje PD, Mackenna DA, Colby TJ, Montag AC, Fujitaki JM, Linemeyer DL, and Bullough DA (2005) Liver-targeted drug delivery using HepDirect prodrugs. *J Pharmacol Exp Ther* **312**:554–560.

Ettmayer P, Amidon GL, Clement B, and Testa B (2004) Lessons learned from marketed and investigational prodrugs. *J Med Chem* **47**:2393–2404.

Fang JY and Leu YL (2006) Prodrug strategy for enhancing drug delivery via skin. *Curr Drug Discov Technol* **3**:211–224.

Farid NA, Kurihara A, and Wrighton SA (2010) Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. *J Clin Pharmacol* **50**:126–142.

Fitzsimmons SA, Lewis AD, Riley RJ, and Workman P (1994) Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase. *Carcinogenesis* **15**:1503–1510.

Fleisher D, Bong R, and Stewart BH (1996) Improved oral drug delivery: solubility limitations overcome by the use of prodrugs. *Adv Drug Deliv Rev* **19**:115–130.

Foster RH, Brogden RN, and Benfield P (1998) Tazarotene. *Drugs* **55**:705–711; discussion 712.

Furfine ES, Baker CT, Hale MR, Reynolds DJ, Salisbury JA, Searle AD, Stadenberg SD, Todd D, Tung RD, and Spaltenstein A (2004) Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. *Antimicrob Agents Chemother* **48**:791–798.

Ganapathy ME and Ganapathy V (2005) Amino Acid Transporter ATB^{0,+} as a delivery system for drugs and prodrugs. *Curr Drug Targets Immune Endocr Metabol Disord* **5**:357–364.

Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, and Desmeules J (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. *N Engl J Med* **351**:2827–2831.

Giraud B, Hebert G, Deroussent A, Veal GJ, Vassal G, and Paci A (2010) Oxazaphosphorines: new therapeutic strategies for an old class of drugs. *Expert Opin Drug Metab Toxicol* **6**:919–938.

Gonzalez FJ and Tukey RH (2006) Drug metabolism, in *Goodman and Gilman's The Pharmacological Basis of Therapeutics* (Brunton LL, Lazo JS, and Parker KL eds) pp 71–91, The McGraw-Hill Companies, Inc., New York.

Granero GE and Amidon GL (2006) Stability of valacyclovir: implications for its oral bioavailability. *Int J Pharm* **317**:14–18.

Gruer PJ, Vega JM, Mercuri MF, Dobrinska MR, and Tobert JA (1999) Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. *Am J Cardiol* **84**:811–815.

Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, et al. (2010) The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. *Cancer Res* **70**:1573–1584.

Guise CP, Wang AT, Theil A, Bridewell DJ, Wilson WR, and Patterson AV (2007) Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia. *Biochem Pharmacol* **74**:810–820.

Hellberg MR, Ke TL, Haggard K, Klimko PG, Dean TR, and Graff G (2003) The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2alpha by human and rabbit ocular tissue. *J Ocul Pharmacol Ther* **19**:97–103.

Hicks KO, Myint H, Patterson AV, Puij FB, Siim BG, Patel K, and Wilson WR (2007) Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. *Int J Radiat Oncol Biol Phys* **69**:560–571.

Society for Cardiovascular Angiography and Interventions, Society of Thoracic Sur-

- geons, Writing Committee Members, Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, and Stein CM (2010) ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. *Circulation* **122**:537–557.
- Hornykiewicz O (2010) A brief history of levodopa. *J Neurol* **257** (Suppl 2):S249–S252.
- Hörter D and Dressman JB (2001) Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. *Adv Drug Deliv Rev* **46**:75–87.
- Hughes B (2010) First oral warfarin alternative approved in the US. *Nat Rev Drug Discov* **9**:903–906.
- Hussain A and Truelove JE (1976) Prodrug approaches to enhancement of physicochemical properties of drugs IV: novel epinephrine prodrug. *J Pharm Sci* **65**:1510–1512.
- Huttunen KM, Mähönen N, Raunio H, and Rautio J (2008) Cytochrome P450-activated prodrugs: targeted drug delivery. *Curr Med Chem* **15**:2346–2365.
- Imai T (2006) Human carboxylesterase isozymes: catalytic properties and rational drug design. *Drug Metab Pharmacokinet* **21**:173–185.
- Imai T, Imoto M, Sakamoto H, and Hashimoto M (2005) Identification of esterases expressed in Caco-2 cells and effects of their hydrolyzing activity in predicting human intestinal absorption. *Drug Metab Dispos* **33**:1185–1190.
- Inturrisi CE, Schultz M, Shin S, Umans JG, Angel L, and Simon EJ (1983) Evidence from opiate binding studies that heroin acts through its metabolites. *Life Sci* **33**:773–776.
- Jordan VC (2007) New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. *Steroids* **72**:829–842.
- Kaback MB, Podos SM, Harbin TS, Jr., Mandell A, and Becker B (1976) The effects of dipivalyl epinephrine on the eye. *Am J Ophthalmol* **81**:768–772.
- Kaukonen KM, Olkkola KT, and Neuvonen PJ (1998) Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. *Eur J Clin Pharmacol* **53**:445–449.
- Khor SP and Hsu A (2007) The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease. *Curr Clin Pharmacol* **2**:234–243.
- Kobayashi M, Takagi M, Fukumoto K, Kato R, Tanaka K, and Ueno K (2008) The effect of buclolone, a CYP2C9 inhibitor, on the pharmacokinetics of losartan. *Drug Metab Pharmacokinet* **23**:115–119.
- Kohn AN, Moss AP, Hargett NA, Ritch R, Smith H Jr, and Podos SM (1979) Clinical comparison of dipivalyl epinephrine and epinephrine in the treatment of glaucoma. *Am J Ophthalmol* **87**:196–201.
- Krämer SD and Testa B (2008) The biochemistry of drug metabolism—an introduction: part 6. Inter-individual factors affecting drug metabolism. *Chem Biodivers* **5**:2465–2578.
- Krise JP and Stella VJ (1996) Prodrugs of phosphates, phosphonates, and phosphinates. *Adv Drug Deliv Rev* **19**:287–310.
- Leenders RG, Damen EW, Bijsterveld EJ, Scheeren HW, Houba PH, van der Meulen-Muileman IH, Boven E, and Haisma HJ (1999) Novel anthracycline-spacer- β -glucuronide, - β -glucoside, and - β -galactoside prodrugs for application in selective chemotherapy. *Bioorg Med Chem* **7**:1597–1610.
- Liederer BM and Borchardt RT (2006) Enzymes involved in the bioconversion of ester-based prodrugs. *J Pharm Sci* **95**:1177–1195.
- Lloyd RV, Duling DR, Rumyantseva GV, Mason RP, and Bridson PK (1991) Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical. *Mol Pharmacol* **40**:440–445.
- MacKenna DA, Montag A, Boyer SH, Linemeyer DL, and Erion MD (2009) Delivery of high levels of anti-proliferative nucleoside triphosphates to CYP3A-expressing cells as a potential treatment for hepatocellular carcinoma. *Cancer Chemother Pharmacol* **64**:981–991.
- Majumdar S, Duvvuri S, and Mitra AK (2004) Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development. *Adv Drug Deliv Rev* **56**:1437–1452.
- Mandell AI, Stentz F, and Kitabchi AE (1978) Dipivalyl epinephrine: a new pro-drug in the treatment of glaucoma. *Ophthalmology* **85**:268–275.
- McClellan K and Perry CM (2001) Oseltamivir: a review of its use in influenza. *Drugs* **61**:263–283.
- Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, et al. (2010) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. *JAMA* **304**:1821–1830.
- Missaghi S, Young C, Fegely K, and Rajabi-Siahboomi AR (2010) Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies. *Drug Dev Ind Pharm* **36**:180–189.
- Müller CE (2009) Prodrug approaches for enhancing the bioavailability of drugs with low solubility. *Chem Biodivers* **6**:2071–2083.
- Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, et al. (2001) Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. *Am J Ophthalmol* **132**:472–484.
- Neuvonen PJ (2010) Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. *Curr Opin Investig Drugs* **11**:323–332.
- Neuvonen PJ, Backman JT, and Niemi M (2008) Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. *Clin Pharmacokinet* **47**:463–474.
- Noble S and Goa KL (1999) Adefovir dipivoxil. *Drugs* **58**:479–487.
- Papot S, Tranoy I, Tillequin F, Florent JC, and Gesson JP (2002) Design of selectively activated anticancer prodrugs: elimination and cyclization strategies. *Curr Med Chem Anticancer Agents* **2**:155–185.
- Patterson AV, Barham HM, Chinje EC, Adams GE, Harris AL, and Stratford IJ (1995) Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). *Br J Cancer* **72**:1144–1150.
- Persson G, Pahlm O, and Gnosselius Y (1995) Oral bambuterol versus terbutaline in patients with asthma. *Curr Ther Res* **56**:457–465.
- Pinto N, Ludeman SM, and Dolan ME (2009) Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy. *Pharmacogenomics* **10**:1897–1903.
- Rautio J (2010) Prodrug strategies in drug design, in *Prodrugs and Targeted Delivery: Towards Better ADME Properties* (Rautio J ed) pp 1–30, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
- Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Järvinen T, and Savolainen J (2008) Prodrugs: design and clinical applications. *Nat Rev Drug Discov* **7**:255–270.
- Reddy KR, Colby TJ, Fujitaki JM, van Poelje PD, and Erion MD (2005) Liver targeting of hepatitis-B antiviral lamivudine using the HepDirect prodrug technology. *Nucleosides Nucleotides Nucleic Acids* **24**:375–381.
- Sachs G, Shin JM, Briving C, Wallmark B, and Hersey S (1995) The pharmacology of the gastric acid pump: the H⁺,K⁺ ATPase. *Annu Rev Pharmacol Toxicol* **35**:277–305.
- Satoh T and Hosokawa M (2006) Structure, function and regulation of carboxylesterases. *Chem Biol Interact* **162**:195–211.
- Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, and La Du BN (2002) Current progress on esterases: from molecular structure to function. *Drug Metab Dispos* **30**:488–493.
- Sawynok J (1986) The therapeutic use of heroin: a review of the pharmacological literature. *Can J Physiol Pharmacol* **64**:1–6.
- Sekino K, Kubota T, Okada Y, Yamada Y, Yamamoto K, Horiuchi R, Kimura K, and Iga T (2003) Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. *Eur J Clin Pharmacol* **59**:589–592.
- Shanghaig A, Yam N and Jasti B (2006) Prodrugs as drug delivery systems, in *Design of Controlled Release Drug Delivery Systems* (Li X and Jasti BR eds) pp 75–106, The McGraw-Hill Company, Inc., New York.
- Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, Akhlaghi F, and Yan B (2006) Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. *J Pharmacol Exp Ther* **319**:1477–1484.
- Shin JM, Cho YM, and Sachs G (2004) Chemistry of covalent inhibition of the gastric (H⁺,K⁺)-ATPase by proton pump inhibitors. *J Am Chem Soc* **126**:7800–7811.
- Sica DA, Gehr TW, and Ghosh S (2005) Clinical pharmacokinetics of losartan. *Clin Pharmacokinet* **44**:797–814.
- Sideras K, Ingle JN, Ames MM, Loprinzi CL, Mrazek DP, Black JL, Weinshilboum RM, Hawse JR, Spelsberg TC, and Goetz MP (2010) Coprescription of tamoxifen and medications that inhibit CYP2D6. *J Clin Oncol* **28**:2768–2776.
- Sinko PJ and Balimane PV (1998) Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats. *Biopharm Drug Dispos* **19**:209–217.
- Sitar DS (1996) Clinical pharmacokinetics of bambuterol. *Clin Pharmacokinet* **31**:246–256.
- Sloan KB and Wasdo S (2003) Designing for topical delivery: prodrugs can make the difference. *Med Res Rev* **23**:763–793.
- Sloan KB, Wasdo SC, and Rautio J (2006) Design for optimized topical delivery: prodrugs and a paradigm change. *Pharm Res* **23**:2729–2747.
- Smith HS (2009) Opioid metabolism. *Mayo Clin Proc* **84**:613–624.
- Sorbera LA, Bayes M, Castaner J, and Silvestre J (2001) Melagatran and ximelagatran: anticoagulant thrombin inhibitor. *Drugs Future* **26**:1155–1170.
- Stamer UM, Zhang L, and Stüber F (2010) Personalized therapy in pain management: where do we stand? *Pharmacogenomics* **11**:843–864.
- Stangier J, Rathgen K, Stähle H, Gansser D, and Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. *Br J Clin Pharmacol* **64**:292–303.
- Stella VJ (2010) Prodrugs: Some thoughts and current issues. *J Pharm Sci* **99**:4755–4765.
- Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H and Tilley JW (2007) *Prodrugs: Challenges and Rewards Part 1 & 2*, Springer Science + Business Media, New York.
- Stella VJ and Nti-Addae KW (2007) Prodrug strategies to overcome poor water solubility. *Adv Drug Deliv Rev* **59**:677–694.
- Susanna R, Jr., Chew P, and Kitazawa Y (2002) Current status of prostaglandin therapy: latanoprost and unoprostone. *Surv Ophthalmol* **47** (Suppl 1):S97–104.
- Svensson LA and Tunek A (1988) The design and bioactivation of presystemically stable prodrugs. *Drug Metab Rev* **19**:165–194.
- Taylor MD (1996) Improved passive oral drug delivery via prodrugs. *Adv Drug Deliv Rev* **19**:131–148.
- Testa B (2004) Prodrug research: futile or fertile? *Biochem Pharmacol* **68**:2097–2106.
- Testa B and Krämer SD (2007) The biochemistry of drug metabolism—an introduction: Part 2. Redox reactions and their enzymes. *Chem Biodivers* **4**:257–405.
- Testa B, and Mayer JM (2003) *Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology*, VCH Verlag Helvetica Chimica Acta AG, Zürich, and Wiley-VCH GmbH & Co. KGaA, Weinheim.
- Tillmann HL (2007) Pradefovir, a liver-targeted prodrug of adefovir against HBV infection. *Curr Opin Investig Drugs* **8**:682–690.
- Timmins GS and Deretic V (2006) Mechanisms of action of isoniazid. *Mol Microbiol* **62**:1220–1227.
- Tirkkonen T and Laine K (2004) Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients. *Clin Pharmacol Ther* **76**:639–647.
- Tirkkonen T, Rynnänen A, Vahlberg T, Irlja K, Klaukka T, Huupponen R, and Laine K (2008) Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study. *Drug Saf* **31**:231–240.
- Tsuda M, Terada T, Irie M, Katsura T, Niida A, Tomita K, Fujii N, and Inui K (2006) Transport characteristics of a novel peptide transporter 1 substrate, antihypoten-

- sive drug midodrine, and its amino acid derivatives. *J Pharmacol Exp Ther* **318**:455–460.
- Tunek A, Levin E, and Svensson LA (1988) Hydrolysis of ³H-bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro. *Biochem Pharmacol* **37**:3867–3876.
- Unadkat JD and Rowland M (1985) Pharmacokinetics of prednisone and prednisolone at steady state in the rabbit. *Drug Metab Dispos* **13**:503–509.
- United States Food and Drug Administration (2006) Summary minutes of the Advisory Committee for Pharmaceutical Science, Clinical Pharmacology Subcommittee. 18–19 October. Available at: <http://www.fda.gov/ohrms/dockets/ac/06/minutes/2006-4248m1.pdf>.
- van De Waterbeemd H, Smith DA, Beaumont K, and Walker DK (2001) Property-based design: optimization of drug absorption and pharmacokinetics. *J Med Chem* **44**:1313–1333.
- Vane JR and Botting RM (2003) The mechanism of action of aspirin. *Thromb Res* **110**:255–258.
- Voronov P, Przybylo HJ, and Jagannathan N (2007) Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer. *Paediatr Anaesth* **17**:684–687.
- Wallentin L (2009) P2Y₁₂ inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. *Eur Heart J* **30**:1964–1977.
- Wathion N (2009) Public statement on possible interaction between clopidogrel and proton pump inhibitors. EMEA/328956/2009. European Medicines Agency, London. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/11/WC500014409.pdf
- Wire MB, Shelton MJ, and Studenberg S (2006) Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. *Clin Pharmacokinet* **45**:137–168.
- Yan YD, Kim HK, Seo KH, Lee WS, Lee GS, Woo JS, Yong CS, and Choi HG (2010) The physicochemical properties, in vitro metabolism and pharmacokinetics of a novel ester prodrug of EXP3174. *Mol Pharm* **7**:2132–2140.
- Zeman EM, Brown JM, Lemmon MJ, Hirst VK, and Lee WW (1986) SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. *Int J Radiat Oncol Biol Phys* **12**:1239–1242.